Javier Sastre, MD, PhD, on Colorectal Cancer: Bevacizumab and FOLFOXIRI in Metastatic Disease
2019 ASCO Annual Meeting
Javier Sastre, MD, PhD, of Hospital Clinico San Carlos, discusses phase III findings on the assessment of circulating tumor cells as a prognostic factor and FOLFOXIRI plus bevacizumab combination outcomes for patients with poor-prognosis colorectal cancer (Abstract 3507).
Richard Pazdur, MD, Director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, discusses the launch of Project Facilitate, a new pilot program to assist oncology health-care professionals in requesting access to unapproved therapies for patients with cancer.
Contact Information for Project Facilitate
Health-Care Professionals
Call: 1-240-402-0004
Patients and Their Families
Call: 301-796-3400
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss phase III study findings on outcomes with combination therapy for intermediate/poor-risk and sarcomatoid subgroups of renal cell carcinoma (Abstract 4500).
Kim N. Chi, MD, of BC Cancer, discusses updated results from a phase II study of cabazitaxel vs abiraterone or enzalutamide in patients with poor-prognosis metastatic castration-resistant prostate cancer (Abstract 5003).
Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, offers commentary on phase III findings from the RELAY study, which showed that erlotinib plus ramucirumab led to superior progression-free survival in previously untreated patients with EGFR mutant–positive NSCLC (Abstract 9000).
Thomas J. George, MD, of NRG Oncology and The University of Florida Health Cancer Center, discusses the initial phase II results from a clinical trial using total neoadjuvant therapy (including veliparib and chemoradiation treatment) for locally advanced rectal cancer (Abstract 3505).